Risk factors associated with relapse in Japanese patients with microscopic polyangiitis

Takashi Wada, Akinori Hara, Yoshihiro Arimura, Kenei Sada, Hirofumi Makino, Koichi Amano, Satoshi Ito, Joichi Usui, Shunichi Kumagai, Shigeto Kobayashi, Yoshinari Takasaki, Kazuo Tanemoto, Hiroaki Dobashi, Masayoshi Harigai, Takao Fujii, Shouichi Fujimoto, Sakae Homma, Eri Muso, Yohko Murakawa, Hidehiro YamadaWako Yumura, Masaharu Yoshida

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective. We retrospectively studied the risk factors associated with relapse during remission maintenance therapy for myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive microscopic polyangiitis (MPA). Methods. Sixty-two patients diagnosed with MPA according to the European Medicines Agency classification algorithm during a 2-year period from January 1, 2005, to December 31, 2006, and who achieved remission after the first remission-induction therapy, were examined (registration no. UMIN000001785). Results. The patient group comprised 25 men and 37 women aged 70.0 ± 8.9 years. The mean observation period was 30.2 ± 15.9 months. The rate of relapse was 24.2% (15/62), and mean interval between remission and relapse was 16.9 ± 13.5 months. During maintenance therapy following remission, the risk of relapse increased when the reduction rate of prednisolone increased above 0.8 mg/month (OR 12.6, 95% CI 2.2-97.9). Proteinuria at the start of maintenance therapy (regression coefficient 1.991 ± 0.758, p <0.05) and the change in red blood cell counts in urine during the period from the start of maintenance therapy to the final observation (regression coefficient 0.126 ± 0.040, p <0.01) were identified as risk factors influencing the vasculitis damage index. Conclusion. In Japan, relapse of MPO-ANCA-positive MPA may be associated with the reduction rate of oral prednisolone administration during maintenance therapy. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)545-551
Number of pages7
JournalJournal of Rheumatology
Volume39
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Microscopic Polyangiitis
Recurrence
Prednisolone
Autoantibodies
Peroxidase
Therapeutics
Observation
Remission Induction
Erythrocyte Count
Rheumatology
Vasculitis
Proteinuria
Oral Administration
Japan
Urine

Keywords

  • Antineutrophil cytoplasmic antibody
  • Microscopic polyangiitis
  • Relapse
  • Risk factors

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. / Wada, Takashi; Hara, Akinori; Arimura, Yoshihiro; Sada, Kenei; Makino, Hirofumi; Amano, Koichi; Ito, Satoshi; Usui, Joichi; Kumagai, Shunichi; Kobayashi, Shigeto; Takasaki, Yoshinari; Tanemoto, Kazuo; Dobashi, Hiroaki; Harigai, Masayoshi; Fujii, Takao; Fujimoto, Shouichi; Homma, Sakae; Muso, Eri; Murakawa, Yohko; Yamada, Hidehiro; Yumura, Wako; Yoshida, Masaharu.

In: Journal of Rheumatology, Vol. 39, No. 3, 03.2012, p. 545-551.

Research output: Contribution to journalArticle

Wada, T, Hara, A, Arimura, Y, Sada, K, Makino, H, Amano, K, Ito, S, Usui, J, Kumagai, S, Kobayashi, S, Takasaki, Y, Tanemoto, K, Dobashi, H, Harigai, M, Fujii, T, Fujimoto, S, Homma, S, Muso, E, Murakawa, Y, Yamada, H, Yumura, W & Yoshida, M 2012, 'Risk factors associated with relapse in Japanese patients with microscopic polyangiitis', Journal of Rheumatology, vol. 39, no. 3, pp. 545-551. https://doi.org/10.3899/jrheum.110705
Wada, Takashi ; Hara, Akinori ; Arimura, Yoshihiro ; Sada, Kenei ; Makino, Hirofumi ; Amano, Koichi ; Ito, Satoshi ; Usui, Joichi ; Kumagai, Shunichi ; Kobayashi, Shigeto ; Takasaki, Yoshinari ; Tanemoto, Kazuo ; Dobashi, Hiroaki ; Harigai, Masayoshi ; Fujii, Takao ; Fujimoto, Shouichi ; Homma, Sakae ; Muso, Eri ; Murakawa, Yohko ; Yamada, Hidehiro ; Yumura, Wako ; Yoshida, Masaharu. / Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. In: Journal of Rheumatology. 2012 ; Vol. 39, No. 3. pp. 545-551.
@article{c24318ae5b4e4ef5b6fd4b47a03de534,
title = "Risk factors associated with relapse in Japanese patients with microscopic polyangiitis",
abstract = "Objective. We retrospectively studied the risk factors associated with relapse during remission maintenance therapy for myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive microscopic polyangiitis (MPA). Methods. Sixty-two patients diagnosed with MPA according to the European Medicines Agency classification algorithm during a 2-year period from January 1, 2005, to December 31, 2006, and who achieved remission after the first remission-induction therapy, were examined (registration no. UMIN000001785). Results. The patient group comprised 25 men and 37 women aged 70.0 ± 8.9 years. The mean observation period was 30.2 ± 15.9 months. The rate of relapse was 24.2{\%} (15/62), and mean interval between remission and relapse was 16.9 ± 13.5 months. During maintenance therapy following remission, the risk of relapse increased when the reduction rate of prednisolone increased above 0.8 mg/month (OR 12.6, 95{\%} CI 2.2-97.9). Proteinuria at the start of maintenance therapy (regression coefficient 1.991 ± 0.758, p <0.05) and the change in red blood cell counts in urine during the period from the start of maintenance therapy to the final observation (regression coefficient 0.126 ± 0.040, p <0.01) were identified as risk factors influencing the vasculitis damage index. Conclusion. In Japan, relapse of MPO-ANCA-positive MPA may be associated with the reduction rate of oral prednisolone administration during maintenance therapy. The Journal of Rheumatology",
keywords = "Antineutrophil cytoplasmic antibody, Microscopic polyangiitis, Relapse, Risk factors",
author = "Takashi Wada and Akinori Hara and Yoshihiro Arimura and Kenei Sada and Hirofumi Makino and Koichi Amano and Satoshi Ito and Joichi Usui and Shunichi Kumagai and Shigeto Kobayashi and Yoshinari Takasaki and Kazuo Tanemoto and Hiroaki Dobashi and Masayoshi Harigai and Takao Fujii and Shouichi Fujimoto and Sakae Homma and Eri Muso and Yohko Murakawa and Hidehiro Yamada and Wako Yumura and Masaharu Yoshida",
year = "2012",
month = "3",
doi = "10.3899/jrheum.110705",
language = "English",
volume = "39",
pages = "545--551",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "3",

}

TY - JOUR

T1 - Risk factors associated with relapse in Japanese patients with microscopic polyangiitis

AU - Wada, Takashi

AU - Hara, Akinori

AU - Arimura, Yoshihiro

AU - Sada, Kenei

AU - Makino, Hirofumi

AU - Amano, Koichi

AU - Ito, Satoshi

AU - Usui, Joichi

AU - Kumagai, Shunichi

AU - Kobayashi, Shigeto

AU - Takasaki, Yoshinari

AU - Tanemoto, Kazuo

AU - Dobashi, Hiroaki

AU - Harigai, Masayoshi

AU - Fujii, Takao

AU - Fujimoto, Shouichi

AU - Homma, Sakae

AU - Muso, Eri

AU - Murakawa, Yohko

AU - Yamada, Hidehiro

AU - Yumura, Wako

AU - Yoshida, Masaharu

PY - 2012/3

Y1 - 2012/3

N2 - Objective. We retrospectively studied the risk factors associated with relapse during remission maintenance therapy for myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive microscopic polyangiitis (MPA). Methods. Sixty-two patients diagnosed with MPA according to the European Medicines Agency classification algorithm during a 2-year period from January 1, 2005, to December 31, 2006, and who achieved remission after the first remission-induction therapy, were examined (registration no. UMIN000001785). Results. The patient group comprised 25 men and 37 women aged 70.0 ± 8.9 years. The mean observation period was 30.2 ± 15.9 months. The rate of relapse was 24.2% (15/62), and mean interval between remission and relapse was 16.9 ± 13.5 months. During maintenance therapy following remission, the risk of relapse increased when the reduction rate of prednisolone increased above 0.8 mg/month (OR 12.6, 95% CI 2.2-97.9). Proteinuria at the start of maintenance therapy (regression coefficient 1.991 ± 0.758, p <0.05) and the change in red blood cell counts in urine during the period from the start of maintenance therapy to the final observation (regression coefficient 0.126 ± 0.040, p <0.01) were identified as risk factors influencing the vasculitis damage index. Conclusion. In Japan, relapse of MPO-ANCA-positive MPA may be associated with the reduction rate of oral prednisolone administration during maintenance therapy. The Journal of Rheumatology

AB - Objective. We retrospectively studied the risk factors associated with relapse during remission maintenance therapy for myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive microscopic polyangiitis (MPA). Methods. Sixty-two patients diagnosed with MPA according to the European Medicines Agency classification algorithm during a 2-year period from January 1, 2005, to December 31, 2006, and who achieved remission after the first remission-induction therapy, were examined (registration no. UMIN000001785). Results. The patient group comprised 25 men and 37 women aged 70.0 ± 8.9 years. The mean observation period was 30.2 ± 15.9 months. The rate of relapse was 24.2% (15/62), and mean interval between remission and relapse was 16.9 ± 13.5 months. During maintenance therapy following remission, the risk of relapse increased when the reduction rate of prednisolone increased above 0.8 mg/month (OR 12.6, 95% CI 2.2-97.9). Proteinuria at the start of maintenance therapy (regression coefficient 1.991 ± 0.758, p <0.05) and the change in red blood cell counts in urine during the period from the start of maintenance therapy to the final observation (regression coefficient 0.126 ± 0.040, p <0.01) were identified as risk factors influencing the vasculitis damage index. Conclusion. In Japan, relapse of MPO-ANCA-positive MPA may be associated with the reduction rate of oral prednisolone administration during maintenance therapy. The Journal of Rheumatology

KW - Antineutrophil cytoplasmic antibody

KW - Microscopic polyangiitis

KW - Relapse

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84857856555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857856555&partnerID=8YFLogxK

U2 - 10.3899/jrheum.110705

DO - 10.3899/jrheum.110705

M3 - Article

C2 - 22174198

AN - SCOPUS:84857856555

VL - 39

SP - 545

EP - 551

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 3

ER -